Taylor CM, Machin S, Wigmore SJ, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37–47.
Zimmerhackl LB, Besbas N, Jungraithmayr T, et al. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost. 2006;32(2):113–120.
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–1687.10.1056/NEJMra0902814
George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666.10.1056/NEJMra1312353
Noris M, Bresin E, Mele C, et al. Atypical hemolytic-uremic syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2017.
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39.10.1007/s00467-015-3076-8
Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67(1):31–42.10.1016/j.molimm.2015.03.246
Ardissino G, Possenti I, Tel F, et al. Time to change the definition of hemolytic uremic syndrome. Eur J Intern Med. 2014;25(2):e29.10.1016/j.ejim.2013.12.002
Sallee M, Ismail K, Fakhouri F, et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol. 2013;14:1126.10.1186/1471-2369-14-3
Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–562.
Hu H, Nagra A, Haq MR, et al. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol. 2014;29(6):1103–1106.
Robitaille P, Gonthier M, Grignon A, et al. Pancreatic injury in the hemolytic-uremic syndrome. Pediatr Nephrol. 1997;11(5):631–632.
Oshima T, Ikutomi M, Shinohara H, et al. Acute myocardial infarction caused by thrombotic microangiopathy complicated with myelodysplastic syndrome. Int Heart J. 2016 Sep 13.
Patschan D, Witzke O, Duhrsen U, et al. Acute myocardial infarction in thrombotic microangiopathies–clinical characteristics, risk factors and outcome. Nephrol Dial Transplant. 2006;21(6):1549–1554.
Kavanagh D. The aHUS rare disease group. 2016. Available from: https://rarerenal.org
Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) controversies conference. Kidney Int. 2016 Dec 15.
Furlan M, Robles R, Galbusera M, et al. von Willebrand Factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578–1584.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–1594.
Vieira-Martins P, El SC, Bordereau P, et al. Defining the genetics of thrombotic microangiopathies. Transfus Apher Sci. 2016;54(2):212–219.
Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–5897.
Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163(4):514–519.
Le QM, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008 Aug;8(8):1694–1701.
Zarifian A, Meleg-Smith S, O’donovan R, et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457–2466.
Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant. 1995 Feb;15(2):247–253.
Fakhouri F, Roumenina L, Provot F, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21(5):859–867.
Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857–868.
Nataatmadja M, Divi D. Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone. Clin Kidney J. 2016;9(4):580–582.
Loupiac A, Elayan A, Cailliez M, et al. Diagnosis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J. 2013;32(10):1045–1049.
Available from: www.ouhsc.edu/platelets/DITMA.htm. 2016.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–2181.
Sayani FA, Abrams CS. How i treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860–3867.
Patriquin CJ, Thomas MR, Dutt T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016 Mar 24.
Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–1753.
Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393–397.
Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284.
Ardissino G, Tel F, Possenti I, et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016 Jan;137(1):1–9.
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19;365(9464):1073–1086.
Freedman SB, Xie J, Neufeld MS, et al. Shiga toxin-producing escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis. 2016 May 15;62(10):1251–1258.
Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol. 2016 Nov;15:1–16.
Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014 Oct;29(10):1967–1978.
Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012 Nov;8(11):643–657.
Povey H, Vundru R, Junglee N, et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. 2014;82(11):326–331.
Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol. 2015;194(11):5129–5138.
Verhave JC, Westra D, van Hamersvelt HW, et al. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. Neth J Med 2013 Sep;71(7):342–347.
Zuber J, Le QM, Morris H, et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando). 2013;27(4):117–125.
Le QM, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013 Mar;13(3):663–675.
Volokhina EB, Westra D, van der Velden TJ, et al. Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission. Clin Exp Immunol. 2014 Jul 31.
Volokhina EB, van de Kar NC, Bergseth G, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015;160(2):237–243.
Servais A, Devillard N, Fremeaux-Bacchi V, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122–2130.
Kelly RJ, Hochsmann B, Szer J, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2015;373(11):1032–1039.
Campistol JM, Arias M, Ariceta G, et al. Actualizacion en sindrome hemolitico uremico atipico: diagnostico y tratamiento. Documento de consenso. Nefrologia. 2015;35:421–447.
